

**TO THE SPANISH NATIONAL SECURITIES MARKET
COMMISSION**

For the purposes set out in Article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services, and related provisions, Faes Farma, S.A. hereby informs the market of the following

OTHER RELEVANT INFORMATION

Faes Farma, S.A. announces that it has entered into an exclusive licence and supply agreement with Dongkook Pharmaceutical for the registration and commercialisation of Uresco in 13 Latin American countries, including Mexico, Colombia, Ecuador, Peru and Chile. Uresco is a fixed-dose combination of dutasteride and tadalafil for the treatment of benign prostatic hyperplasia.

Under the agreement, Dongkook Pharmaceutical will supply the finished product to Faes Farma, which will be responsible for registration and marketing in the markets covered by the licence. The licence will run for ten years from the product's commercial launch.

The collaboration includes an upfront payment as well as additional payments linked to the granting of regulatory approvals and the achievement of certain commercial milestones, totalling up to EUR 2 million, and a long-term revenue-sharing structure aligned with the commercial success of the product.

The product was approved in South Korea in January 2025, and Faes Farma will commence the necessary regulatory processes for its commercialisation in Latin America.

A press release is attached below

Faes Farma, S.A.

1st July 2026

Faes Farma advances its international expansion through an agreement to commercialise a new urology treatment in Latin America

- **The company has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical to register and commercialize Uresco in 13 Latin American countries.**
- **The agreement includes a total amount of up to EUR 2 million, linked to obtaining regulatory registrations and meeting commercial milestones that reflects both parties' commitment to the progressive development of Uresco across the region.**
- **The partnership enables Faes Farma to expand its portfolio in Latin America and reinforces its position as a partner of choice in this market.**

Bilbao, July 1st, 2026. - Faes Farma has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical for the commercialisation of Uresco in Latin America. Uresco is a fixed-dose combination of dutasteride and tadalafil indicated for the treatment of benign prostatic hyperplasia (BPH), one of the most common urological conditions affecting men over the age of 50.

The licence, which will remain in force for ten years from the product's commercial launch, covers 13 Latin American countries, including Mexico, Colombia, Ecuador, Peru and Chile. Under the terms of the agreement, Dongkook Pharmaceutical will supply the finished product to Faes Farma, which will be responsible for its registration and commercialisation in the licensed territories.

The collaboration includes an upfront payment as well as additional milestone payments tied to regulatory approvals and commercial sales achievements, up to a total amount to EUR 2 million and a long-term revenue-sharing structure aligned with the commercial success of the product. This structure reflects the commitment of both companies to the progressive development of Uresco across Latin American markets.

Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland. It can have a significant impact on patients' quality of life, causing bothersome urinary symptoms that negatively affect their wellbeing. The condition represents a sizeable and growing market in Latin America, driven by its high prevalence, an ageing population and the need for new therapeutic alternatives. In this context, Faes Farma is adding a differentiated product to its portfolio, supported by clinical evidence and aligned with the needs of both specialists and patients.

The agreement also reinforces Faes Farma's position in Latin America, a region that has become the Group's main driver of organic growth. The company's strategic presence in urology was previously strengthened through a collaboration agreement with Japanese pharmaceutical company Kyorin Pharmaceutical for the commercialisation of Uritos (imidafenacin), an innovative treatment for overactive bladder.

The addition of Uresco further underlines Faes Farma's commitment to specialising in high-value urology solutions and strengthens its role as a partner of choice for

international pharmaceutical companies seeking to develop commercial opportunities in the region.

"In Latin America, we have a well-established network, regulatory expertise and a strong local presence. These capabilities enable us to support the development of innovative products and bring new therapeutic alternatives closer to patients and healthcare professionals. Through this agreement, we continue advancing towards our goal of being recognised as the leading Spanish pharmaceutical company on a global scale," said Eduardo Recoder, CEO of Faes Farma.

Uresco was developed by Dongkook Pharmaceutical and is supported by a Phase III clinical trial involving 667 patients with 48 weeks of follow-up, which demonstrated its superiority over the respective monotherapies. Its benefits include rapid improvement of urinary symptoms, reduction in prostate volume and disease progression, as well as improvements in sexual function associated with BPH. The treatment was approved in South Korea in January 2025, and Faes Farma will now begin the regulatory processes required for its commercialisation in the Latin American markets covered by the agreement.

About Faes Farma

We are a company with more than 90 years of experience and a presence in more than 130 countries through marketed or licensed products. We combine passion, science, and innovation to transform people's health. We research, produce, and market prescription medicines, healthcare products, and animal nutrition products, and we aspire to become a leading pharmaceutical group in excellence and innovation. At Faes Farma, we are guided by our values to offer the highest quality solutions in health and well-being, with the patient as our priority; to develop innovative products that adapt to the needs of society; and to guarantee integrity, transparency, and commitment through responsible management and excellence.

About Dongkook Pharmaceutical

DongKook Pharmaceutical is a leading South Korean pharmaceutical company founded in 1968 and headquartered in Seoul, Republic of Korea. With more than five decades of experience, the company is engaged in the research, development, manufacturing and commercialization of prescription medicines, consumer healthcare products, medical devices and active pharmaceutical ingredients. Guided by its philosophy of "Human & Life" and its commitment to improving patients' quality of life, DongKook Pharmaceutical continues to expand access to innovative and high-quality healthcare solutions across global markets.

Press contact

María Marín
Investor Relations and External Communications Director
mmarin@faes.es
Faes Farma

Paula Lacruz
placruz@harmon.es
626 12 93 00
Harmon Corporate Affairs